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The chronic subdural hematoma (cSDH)-Drain trial compared recurrence rates and 2 
clinical outcome associated with the use of subperiosteal drain (SPD) and subdural 3 
drain (SDD) after burr-hole drainage for cSDH. This subgroup analysis aimed to 4 
determine, whether one drain type is preferable for patients treated with platelet 5 
inhibitors (PI) or anticoagulants (AC). 6 
This subanalysis included 133 patients treated withPI/AC of the 220 patients from the 7 
preceding cSDH-Drain trial. For these patients the association between the drain type 8 
used and recurrence rates, mortality, as well as clinica  outcome at 6 weeks and 12 9 
months follow-up were analyzed using a logistic regression analysis model. 10 
Additionally, recurrence rates, clinical outcome, and mortality were assessed for each 11 
PI or AC type separately. 12 
The insertion of SPD was associated with 7.35% recur nce rates compared to 13.85 13 
% with SDD in patients treated with PI or AC (OR 0.41, 95% CI 0.06 – 2.65, p=0.36). 14 
Outcome measurements and mortality did not differ significantly between both 15 
groups at 6 weeks and 12 months follow up. In addition, there was no statistically 16 
significant association between drain type and recur nce rate or mortality when 17 
comparing data for each PI or AC type. At 24 hours after surgery, significantly more 18 
patients under phenprocoumon and natrium-dalteparin h d a GCS between 13 and 15 19 
in the SDD group compared to the SPD group (p=0.006), while at 6 weeks follow up 20 
significantly more patients in the SDD group treated with ASA had a good mRS 21 
(p=0.01). At 12 months no significant difference in outcome measurements was seen 22 
for all PI and AC types 23 
In patients treated with PI or AC, the insertion of SPD after burr-hole drainage of 24 
cSDH showed comparable recurrence, mortality, and lo g term outcome rates when 25 
compared to SDD. 26 
 27 
 28 
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Introduction 1 
           Chronic subdural hematoma (cSDH) represents, with an incidence of 1.7-13.1 2 
per 100,000 inhabitants per year, one of the most cmmon neurosurgical conditions 3 
especially among the elderly population1,2,3,4,5. In patients with neurological 4 
symptoms, burr-hole drainage and drain insertion is the most common treatment 5 
modality6. The insertion of a drain was shown to be associated with lower recurrence 6 
and mortality rates at 6 months2. We recently published the results of a randomized 7 
controlled trial (cSDH-Drain Trial) comparing the use of subperiosteal drain (SPD) 8 
and subdural drain (SDD) after burr hole drainage of cSDH7. When compared to 9 
SDD, SPD led to similar recurrence rates, while the rat  of infections and iatrogenic 10 
brain injuries was significantly reduced7. The ideal treatment modality for patients 11 
with cSDH under platelet aggregation inhibitors (PI) or anticoagulants (AC) remains 12 
unclear8,9. Since SPD is not positioned in direct contact to cortical structures, bridging 13 
veins, or hematoma membranes, it might be favourable to SDD, especially in this 14 
group of patients who seemingly suffer a higher risk for bleeding and recurrence. On 15 
the other hand, SDD which is placed directly within the hematoma cavity, might lead 16 
to lower recurrence rates in this group of patients, who are potentially prone to more 17 
recurrence rates. We therefore performed a post-hoc subanalysis of this sub-group of 18 




This is a subanalysis of the preceding cSDH-Drain trial7. The detailed study 23 
design, methodology and results have been presented rec ntly10,7 In brief, the cSDH-24 
Drain trial was a two-centre, prospective, randomized trial including 220 patients with 25 
symptomatic cSDH requiring surgical evacuation. After burr-hole drainage, patients 26 
were randomly assigned to receive either a subdural d in (SDD-group) or a 27 
subperiosteal drain (SPD-group). The primary endpoint was symptomatic recurrence 28 
requiring a reoperation within 12 months. Secondary outcomes included clinical and 29 
radiological outcome, morbidity and mortality rates, and length of stay. Follow up 30 
time for all patients was 12 months postoperatively. Of 262 screened patients, 220 31 
were randomized to receive either SPD or SDD. All patients were included in the 32 
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final analysis (120 SPD and 100 SDD, for further details please refer to Soleman et al. 1 
Figure 2)7. Recurrence rate was lower in the SPD group (8.33%, 95% confidence 2 
interval [CI] 4.28-14.72) than in the SDD group (12.00%, 95% CI 6.66-19.73), with 3 
the treatment difference (3.67%, 95% CI -12.6-5.3) not meeting predefined 4 
noninferiority criteria7 . The SPD group showed significantly lower rates of surgical 5 
infections (p = 0.04) and iatrogenic morbidity through drain placement (p = 0.02). 6 
Length of stay and mortality rates were comparable in both groups.  7 
Similarly to the initial study, for this subanalysis recurrence was defined as 8 
cSDH diagnosed on CT or MRI on the same side as the initial operation, with new or 9 
progressing clinical symptoms requiring surgical trea ment. Indications for blood 10 
thinners are described in Supplementary Table 1. As defined in the main study 11 
protocol10, AC medication was reversed preoperatively using Vitamin-K substitution 12 
(e.g. Konakion) and/or coagulant-factors (e.g. beripl x) aiming for an international 13 
normalized ratio (INR) of <1.3. In case of DOACS and PI medication, the decision 14 
whether reversal medication should be applied was left for the treating surgeon, since 15 
standard reversal treatment was not defined within the protocol of the main trial. Due 16 
to the lack of supporting data, reversal treatment using tranexanic-acid (e.g. 17 
cyclocaprone), minirin, platelet transfusion, and/or Vitamin-K substitution is rarely 18 
used at our institutions. Resumption of AC/PI medication was defined within the main 19 
study protocol. AC was resumed no earlier than six weeks postoperatively. PI 20 
medication was resumed no earlier than two weeks posto eratively, while in cases of 21 
PI treatment as a primary prophylaxis, postoperative discontinuation of up to six 22 
weeks was tolerated. 23 
Compliance with ethical standards 24 
Informed consent: Written informed consent of the patient or the next-of-kin (in 25 
comatose or incompetent patients) was obtained by amember of the neurosurgical 26 
staff prior to randomization. 27 
Conflict of Interest: None.  28 
Disclosure of Funding: This study was funded by the R search Foundation 29 
Kantonsspital Aarau. The funder of the study had no role in study design, data 30 
collection, data analysis, data interpretation, or w iting of the report. The 31 
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corresponding author had full access to all data in the study and had final 1 
responsibility for the decision to submit for publication.  2 
Ethical approval: The trial was done and analyzed according to the STROBE 3 
guidelines. The study protocol was approved by the local ethics committees 4 
(Ethikkommission Nordwest- und Zentralschweiz, Switzerland) 5 
 6 
Statistical analysis 7 
The associations between recurrence rates, mortality (corrected for the patients 8 
age), and the drain type inserted were analysed using a logistic regression model. 9 
Clinical outcome, including Glasgow Coma Scale (GCS), modified Rankin scale 10 
(mRS), Glasgow Outcome Scale (GOS), and Markwalder Sco e (MWS) at 24 hours, 6 11 
weeks and 12 months after surgery for the two drain types were compared and 12 
analysed using the chi square test. For analysis, the outcome scores were 13 
dichotomized as follows: GCS 13-15 and <13, mRS ≤ 3 and >3, GOS >3 and ≤3, and 14 
MWS ≥1 and <1. The risk for recurrence or mortality in patient with a specific PI or 15 
AC (acetylsalicylic acid (ASA; Aspirn Cardio®, Bayer Schweiz AG), natrium-16 
dalteparin (Fragmin®, Pfizer PFE Switzerland GmbH) and phenprocoumonum 17 
(Marcoumar®, MEDA Pharma GmbH), clopidogrel, different oral anticoagulants 18 
(DOAC; including: acenocumarol (Sintrom®, Medius AG), rivaroxaban (Xarelto®, 19 
Bayer Schweiz AG), fondaparinux (Arixtra®, Aspen Pharma Schweiz GmbH), 20 
apixaban (Eliquis®, Bristol-Myers Squibb SA)) were compared to patients without PI 21 
or AC using a multivariate logistic model. Finally, the interaction between the type of 22 
drain inserted and recurrence rate for each PI/AC type was analyzed using a 23 
likelihood ratio test comparing the model with interaction and the model without 24 
interaction. Patients treated with two concurrent PI/ACs (e.g. ASA and 25 
phenprocoumonum) were included for the analysis in the more “aggressive” PI or AC 26 
group type. ASA was assessed as the least aggressive, ince its effect on perioperative 27 
bleeding and recurrence was estimated the lowest, followed by clopidogrel, prasugrel, 28 
phenprocoumonum, and natrium-dalteparin. A p-value <0.05 was considered 29 
significant. All statistical analyses were done using R (Comprehensive R Archive 30 
Network (CRAN), R Foundation for Statistical Computing, Vienna, Austria, Version 31 
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3.2.2). The analyses were performed on the per protocol analysis set as defined for the 1 
main trial analysis. 2 
Results 3 
Among the 220 study participants recruited between April 15, 2013, and 4 
December 9, 2015, 133 patients (60.5%) were treated with PI or AC. Of these, 65 5 
(48.9%) patients received an SDD, while 68 (51.1%) patients received an SPD, 6 
respectively. Baseline subgroup characteristics are presented in Table 1, while 7 
distribution of drain type and PI/AC types are shown in Table 2.  8 
Recurrence rates and Mortality 9 
The insertion of SPD was associated with 7.35% recur nce rates compared to 10 
13.85 % with SDD in patients treated with PI or AC, however this difference was not 11 
statistically significant (OR 0.41, 95% CI 0.06 – 2.65, p=0.36) (Table 3). For patients 12 
treated with PI or AC, mortality rate did not differ significantly between the SDD and 13 
SPD group (9.2%, n=6 vs. 11.7%, n=8, OR 3.01, 95% CI 0.45 - 22.08, p=0.26). 14 
Causes for death in the SDD group were one intracerebral bleeding under DOAC, one 15 
stroke under clopidogrel, one natural death under Vitamin K antagonists, one 16 
empyema under clopidogrel, one cancer death under ASA. Causes for death in the 17 
SPD group were  one multiple organ failure under DOAC, one leucemia death under 18 
Vitamin K antagonists, one postoperative intracranial bleeding under ASA, one 19 
multiple organ failure under ASA, one natural death under ASA, one cardiac failure 20 
under Aspirin, one natural death under DOAC and one death of unknown cause under 21 
ASA and Vitamin K antagonists. Older patients showed g nerally higher mortality 22 
rates (p=0.01); nevertheless after correcting for age, the drain type did not influence 23 
significantly mortality rates (Table 3). The logistic model showed similar recurrence 24 
rates (Table 4) and higher mortality rates in patients treated with DOAC (OR 4.21 CI 25 
[0.98-16.48], p=0.04) compared to patients without PI or AC (Table 5). The 26 
likelihood ratio test showed no interaction between the type of drain inserted and type 27 
of PI/AC for recurrence of cSDH (p=0.20) and mortality at 12 months (p=0.81). 28 
Clinical outcome 29 
Generally, when patients were under PI or AC, at 24hours, 6 weeks and 12 30 
months follow-up, GCS, mRS and GOS did not differ significantly between the two 31 
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groups (Table 6). After comparing outcome for each PI or AC type separately, at 24 1 
hours after surgery, significantly more patients under phenprocoumonum and 2 
natrium-dalteparin had a GCS between 13 and 15 in the SDD group compared to the 3 
SPD group (p=0.006), while at 6 weeks follow up signif cantly more patients in the 4 
SDD group treated with ASA had a good mRS (p=0.01) (Table 6). At 12 months no 5 
significant difference in outcome measurements was seen for all PI and AC types. 6 
Discussion 7 
         To date, the cSDH-Drain trial is the largest randomized study comparing 8 
recurrence rates of surgically drained cSDH after th  insertion of SPD or SDD. In 9 
daily neurosurgical practice, we are often confronted with cSDH patients treated with 10 
PI and/or AC; therefore, it is not surprising that 60.5% of our study participants 11 
received PI or AC. With this subanalysis, we intendd to evaluate an additional aspect 12 
that might influence the treatment of cSDH in a subgroup of patients, where to date 13 
no guidelines exist and the literature is sparse. According to our results, in patients 14 
treated with PI or AC undergoing burr hole drainage of cSDH, recurrence rates were 15 
lower in the SPD group compared to the SDD group; however significance was not 16 
seen. Similarly, at 12 months follow up, no statistically significant association 17 
between mortality rates and the inserted drain typewere seen. Patients treated with 18 
DOAC showed a strong association with mortality, while the drain type in DOAC 19 
patients did not influence mortality rates. For all PI or AC types no statistically 20 
significant association between the drain type inserted and recurrence or mortality 21 
rates was apparent. Patients from the SDD group who were under 22 
phenprocoumonum/natrium-dalteparin or acetylsalicylic acid showed significantly 23 
higher rates of good GCS at 24 hours, and good mRS at 6 weeks follow up. 24 
Otherwise, outcome measurements did not differ significa tly between both groups. 25 
 26 
Recurrence rates  27 
Similar to the recurrence rates within the main study, in the subgroup of 28 
patients treated with PI or AC, SPD was associated with lower recurrence rates 29 
compared to SDD, although significance was not reach d. This might be explained by 30 
the fact that the SPD insertion technique is associated with less subdural 31 
manipulation. Therefore, the risk of injuring bridgn  veins or cortical vessels, which 32 
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might predispose acute or chronic rebleeds, is smaller. A few studies compared 1 
recurrence rates in patients undergoing burr hole drainage for cSDH who received 2 
PI8,9 or oral anticoagulants11; however none of them investigated the association with 3 
the inserted drain type12,13. According to the literature, when evaluating recurrence 4 
rates of cSDH after SPD insertion compared to SDD insertion, most authors 5 
emphasize comparable recurrence rates with both drainage types5,14,15,16,17,18,19,20 or in 6 
some cases lower recurrence rates with SPD16.  Therefore, it is not surprising that 7 
patients who might have a higher bleeding risk, dueto PI or AC therapy, would also 8 
benefit from a less invasive drain insertion technique. 9 
Clinical outcome and mortality 10 
To our knowledge, there are no studies focusing on the outcome and mortality 11 
in patients undergoing burr hole drainage, who are under PI or AC, depending on the 12 
inserted drain type. At 24 hours, 6 weeks, and 12 months follow up, clinical outcome 13 
was overall comparable in both groups. No difference was seen between the groups in 14 
mortality rates at 12 months either. These findings are in accordance with the results 15 
of our main trial, where clinical outcome and mortality did not differ between the 16 
SPD and SDD group. Interestingly, 24 hours after surgery significantly more patients 17 
under phenprocoumonum/ natrium-dalteparin treatment achieved a GCS of 13-15 in 18 
the SDD group compared to the SPD group, while at 6 weeks follow up significantly 19 
more patients in the SDD group treated with ASA showed higher mRS scores. 20 
Comparing our results to external data and interpreting them is difficult, as the current 21 
study is the first one to investigate specifically this question. Previous reports describe 22 
lower mortality, less complications, and significantly better mRS at 6 months after 23 
insertion of SPD compared to SDD5,18. However, within these studies the intake of 24 
blood thinners was not specifically assessed. Our results might have been skewed by 25 
the rather small sample size of the medication-subgroups. Therefore, trials with larger 26 
cohorts are definitely needed to confirm our findings. Lastly, even though some 27 
differences between the two drain groups for the short term clinical outcome for some 28 
PI/AC medications were found, the long-term clinical follow up could not detect these 29 
differences in clinical outcome between the drain groups anymore. 30 
 31 
Recurrence rates and mortality according to the type of blood thinner  32 
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No statistically significant association between drainage type and different 1 
types of PI or AC for recurrence and mortality was found. However, we observed 2 
generally a higher mortality in patients treated with DOAC compared to patients 3 
without anticoagulation, irrespective of the drainage type. Since the patients were not 4 
randomly assigned to their medical treatment, this comparison is most likely 5 
confounded. Probably, patients treated with DOAC were in general sicker, and 6 




Although this subanalysis is based on a large, randomized controlled trial, 11 
some limitations exist. First, the main study was not initially designed to test the 12 
associations between drain types and PI/IC, so that the conclusions of this post-hoc 13 
subanalysis might not be statistically confirmatory. Exact data on the perioperative 14 
discontinuation or postoperative resumption time of PI or AC was not available. In 15 
addition, reversal treatment for PI and DOACS (e.g. cyclocapron, minirin, platelet 16 
transfusion etc.), was based on the decision of the treating surgeon and not collected 17 
or documented in a systematic manner. However, the protocol of the main study 18 
defined discontinuation margins for both. Finally, the dose of the applied PI or AC 19 
was not assessed, which might have skewed our results as well. Strengths of this 20 
study are the highly relevant subset of data, present d from the largest RCT analysing 21 
recurrence rate and outcome after surgical drainage of cSDH and insertion of SPD 22 
compared to SDD. To date, this is the first study analysing which drain type seems to 23 
be more suitable for patients undergoing burr hole drainage of cSDH treated with PI 24 
or AC.  25 
Conclusion 26 
In patients treated with PI and/or AC, the insertion of SPD after burr-hole 27 
drainage of cSDH showed comparable recurrence, mortality, and long term outcome 28 
rates when compared to SDD. These findings, in conjunction with the initial findings 29 
of the cSDH-Drain trial, might suggest that the insertion of SPD may be warranted 30 
also in patients treated with PI or AC. 31 
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Age (mean ± SD) 80.1 (±7.3) 77.9 (±9.7) 0.02 
Sex (male) n (%) 47 (73.4) 46 (67.6) 1 
Comorbidities n (%)    




• Dementia 8 (12.5) 6 (8.8) 0.26 
• Liver cirrhosis 0 1 (1.5) 0.59 
• Obesity 2 (3.1) 3 (4.4) 0.46 
• AF 20 (31.2) 23 (33.8) 0.84 
• Smoking 2 (3.1) 3 (4.4) 0.92 
• Drug abuse 0 0 1 
• Alkohol abusus 5 (7.8) 0 0.14 
• CAD 6 (9.4) 4 (5.9) 0.53 
• Stroke 10 (15.6) 13 (19.1) 0.75 
• PE 2 (3.1) 5 (7.4) 0.73 
• DVT 2 (3.1) 6 (8.8) 0.30 
Symptoms     
• Coma n (%) 3 (4.6) 2 (2.9) 0.52 
• Incontinence n (%) 2 (3.1) 1 (1.5) 0.85 
• Sensory deficit n (%) 3 (4.6) 5 (7.4) 0.63 
• others n (%) 0 1 (1.5) 0.87 
Outcome meassurments preop    
• GCS median (mean [IQR]) 14 [14; 15] 15 [14; 15] 0.29 
• mRS (1-3) n (%) 49 (76.6) 47 (69.1) 0.39 
• GOS (4-5) n (%) 45 (70.3) 45 (66.2) 1 
• Markwalder score (0-1) n (%) 19 (29.7) 22 (32.8) 0.77 
Hematoma characteristics    
• Midline shift (mean ± SD) 8.3 (±5.3) 6.8 (±4.5) 0.10 
• Hemorrhage width mm (mean ± 
SD) 
21.4 (±6.3) 18.3 (±5.9) 
 
- right (mean ± SD) 19.8 (±5.6) 18.3 (±6.8) 0.44 
- left (mean ± SD) 21.7 (±7.2) 17.9 (±5.5) 0.01 
• Bilateral hemorrhage n (%) 14 (21.9) 15 (22.1) 1.0 
 
Table 1. Baseline characteristics of each drain type 
 
SDD: subdural drain; SPD: subperiosteal drain; n: number; AF: atrial fibrillation; COPD: 
chronic obstructive pulmonary disease; CAD: coronary tery disease; PE: pulmonary 
embolism; DVT: deep vein thrombosis; GCS: Glasgow Coma Scale; mRS: modified Rankin 
scale; GOS: Glasgow Outcome Score 
 







Acetylsalicylic acid 22 (33.8) 27 (40) 
Natrium-dalteparin 1 (1.5) 2 (2.9) 
Phenprocoumonum 21 (32.3) 20 (29.4) 
Clopidogrel 4 (6.2) 4 (5.9) 
DOAC 7 (10.8) 8 (11.8) 
Acetylsalicylic acid and natrium-dalteparin 1 (1.5) 0 
Acetylsalicylic acid and phenprocoumonum 2 (3.1) 3 (4.4) 
Acetylsalicylic acid and clopidogrel 5 (7.7) 4 (4.9) 
Acetylsalicylic acid and prasugrel 1 (1.5) 0 
 
Table 2. Distribution of drainage type and PI/AC 
 
PI: platelet inhibitors; AC: anticoagulants; SDD: subdural drain; SPD: subperiosteal drain; n: 
number; DOAC: different anticoagulants¨ 
All values: n (%)  
 
Table 3. Associations between recurrence rates, mortality and PI/AC according to the 
drain type 
PI: platelet inhibitors; AC: anticoagulants; SDD: subdural drain; SPD: subperiosteal drain CI: 




Term Variables OR [95% CI] p-value 
Estimated association between recurrence rates, drain type 
and use of PI/AC 
SPD (vs. SDD) 0.41[0.06; 2.65] 0.36 
Estimated association between mortality, drain type and use 
of PI/AC 
SPD (vs. SDD) 3.01 [0.45; 22.08] 0.26 
Estimated association between mortality, drain type and use 
of PI/AC corrected for age 
PI or AC/age 1.19 [0.47;1.16] 0.73 
 
Type of PI/AC Logistic model (PI/AC type compared to no PI/AC) 
 OR (95% CI) p-value 
Acetylsalicylic acid/ 
clopidogrel/prasugrel 
1.36 (0.47-3.89) 0.56 
Phenprocoumonum/natrium-
dalteparin 
0.87 (0.22-2.92) 0.83 
DOAC 1.54 (0.22-7.03) 0.61 
 
Table 4. Distribution of recurrence rates at 12 months according to PI or AC type and drain 
type (logistic model analysis) 
PI: platelet inhibitor; AC: anticoagulants; DOAC: other anticoagulants; SPD: subperiosteal drain; 
SDD: subdural drain; n: number 
*patients with concurrent acetylsalicylic acid treatment included in these groups 
(Phenprocoumonum/natrium-dalteparin group: 3 patients with SPD and 3 patients with SDD; 




PI/AC type Logistic model (PI/AC type compared to no PI/AC) 
 OR (95% CI) p-value 
Acetylsalicylic acid/ 
clopidogrel/prasugrel 
1.57 (0.53-4.71) 0.41 
Phenprocoumonum/natrium-
dalteparin 
0.74 (0.15-2.80) 0.67 
DOAC 4.21 (1.06-16.73) 0.04 
 
Table 5. Distribution of mortality rates at 12 months according to PI or AC type and drain type 
(logistic model analysis). 
PI: platelet inhibitor; AC: anticoagulants; DOAC: other anticoagulants; SPD: subperiosteal drain; 
SDD: subdural drain; n: number; 
*patients with concurrent acetylsalicylic acid treatment included in these groups 
(Phenprocoumonum/natrium-dalteparin group: 3 patients with SPD and 3 patients with SDD; 












F/U time SPD SDD p-value SPD SDD p-value SPD SDD p-value SPD SDD p-value SPD SDD p-value 
 GCS (13-15) 
24h 56 (82.3) 59 (92.2) 0.12 20 (74.1) 20 (90.9) 0.16 21 (84.0) 25 (100) 0.006 8 (100) 10 (100) 1 7 (87.5) 4 (57.1) 0.28 
6w 62 (96.9) 55 (94.8) 0.66 23 (95.6) 19 (100) 1 24 (100) 24 (96.0) 1 7 (87.5) 8 (100) 1 8 (100) 4 (66.7) 0.16 
12m 54 (98.2) 51 (100) 1 21 (95.5) 18 (100) 1 21 (100) 20 (100) 1 7 (100) 8 (100) 1 5 (100) 5 (100) 1 
 mRS (≤3) 
24h 49 (72.6) 53 (82.8) 0.15 17 (63.0) 16 (72.7) 0.55 20 (80.0) 23 (92.0) 0.42 8 (100) 10 (100) 1 4 (50.0) 4 (57.1) 1 
6w 53 (82.8) 55 (94.8) 0.05 17 (70.8) 19 (100) 0.01 22 (91.7) 24 (96.0) 0.61 8 (100) 8 (100) 1 6 (75.0) 4 (66.7) 1 
12m 46 (83.4) 47 (92.2) 0.24 18 (81.8)  16 (88.9) 0.67 16 (76.2) 19 (95.0) 0.18 7 (100) 7 (87.5) 1 5 (100) 5 (100) 1 
 GOS (>3) 
24h 54 (79.4) 55 (85.9) 0.37 24 (88.9) 17 (77.3) 0.44 19 (76.0) 24 (96.0) 0.09 7 (87.5) 10 (100) 0.44 4 (50.0) 4 (57.1) 1 
6w 50 (78.1) 51 (87.9) 0.23 15 (62.5) 18 (94.7) 0.03 22 (91.7) 24 (96.0) 0.61 7 (87.5) 7 (87.5) 1 6 (75.0) 2 (33.3) 0.28 
12m 46 (83.4) 45 (88.2) 0.58 16 (72.7) 15 (83.3) 0.48 20 (95.2) 19 (95.0) 1 6 (85.7) 7 (87.5) 1 5 (100) 4 (80.0) 1 
 Markwalder score (≥1) 
24h 43 (63.2) 45 (70.3) 0.46 12 (44.4) 13 (59.1) 0.4 19 (76.0) 21 (84.0) 0.73 8 (100) 7 (70.0) 0.22 4 (50.0) 4 (57.1) 1 
6w 54 (84.4) 49 (84.5) 1 18 (75.0) 18 (94.7) 0.11 22 (91.7) 23 (92.0) 1 7 (87.5) 5 (62.5) 0.57 7 (87.5) 3 (50.0) 0.24 
12m 48 (87.3) 45 (88.2) 1 18 (81.8) 15 (83.3) 1 20 (95.2) 19 (95.0) 1 6 (85.7) 7 (87.5) 1 4 (80.0) 4 (80.0) 1 
 Total (n) 
24h 68 64  27 22  25 25  8 10  8 7  
6w 64 58  24 19  24 25  8 8  8 6  
12m 55 51  22 18  21 20  7 8  5 5  
 
Table 6.  Distribution of outcome measurements for PI/AC type and type of drain inserted 
F/U: follow up; PI: platelet inhibitor; AC: anticoagulants; DOAC: other anticoagulants; SPD: subperiosteal drain; SDD: subdural drain; n: number; h: hours; w: 
weeks; m: months; GCS: Glasgow Coma Scale; GOS: Glasgow Outcome Scale; mRS: modified Rankin Scale 
*patients with concurrent acetylsalicylic acid treatment included in these groups (Phenprocoumonum/natrium-dalteparin group: 3 patients with SPD and 3 
patients with SDD; Clopidogrel/prasugrel group: 4 patients with SPD and 6 patients with SDD) 
Bold: significant 












clopidogrel/prasugrel n (%) 
  
 
• Primary prophylaxis 9 (12.5) 10 (14.7)  
• CAD 9 (14.1) 9 (13.2)  
• CVI 4 (6.3) 5 (7.4)  
• Carotid stenosis 2 (3.1) 1 (1.5)  
• unknown 1 (3.1) 2 (2.9)  
• AF 1 (1.6)   
• Polycythaemia vera  1 (1.5)  
• Vascular dementia  1 (1.5)  
• TIA  2 (2.9)  
• PAOD 1 (3.1)   
Acetylsalicylic acid/ + 
clopidogrel/prasugrel n (%) 
  
 
• PAOD 1 (1.6)   
• CAD 2 (3.1) 2 (2.9)  
• TEA 1 (1.6)   
• CVI 1 (1.6)   
• Coiling of an intracranial aneurysm  1 (1.5)  
Acetylsalicylic acid/ + 
Phenprocoumonum n (%) 
  
 
• CAD 1 (1.6) 1 (1.5)  
• Jugular vein thrombosis 1 (1.6)   
• CVI  1 (1.5)  
• AF  1 (1.5)  





• AF 13 (20.3) 15 (22)  
• Faktor V Leiden mutation 1 (1.6)   
• PE 3 (4.7) 3 (4.4)  
• Sinus vein thrombosis 1 (1.6)   
• unknown 1 (1.6)   
• CAD 3 (4.7)   
• Bone fracture  1 (1.5)  
• DVT  3 (4.4)  
• Pulmonary hypertension  1 (1.5)  
DOAC n (%)    
• AF 5 (7.8) 5 (7.4)  
• uknown 1 (1.6) 1 (1.5)  
• DVT  1 (1.5)  
• Bone fracture 1 (1.6) 1 (1.5)  
    
 
Supplementary Table 1 Indications for blood thinners 
 
SDD: subdural drain; SPD: subperiosteal drain; n: number; AF: atrial fibrillation; COPD: 
chronic obstructive pulmonary disease; CVI: cerebral vascular infarction; CAD: coronary 
artery disease; PE: pulmonary embolism; DVT: deep vein thrombosis; PAOD: peripheral 
arterial occlusive disease; TEA: carotid thromboendarterectomy 
Abbreviations list 














Chronic subdural hematoma 








Glasgow Coma Scale 









DOAC Different Oral Anticoagulation 
 
OR time Operation time 
 
PBC Packed Blood Cells 
 
PI Platelet Inhibitors 
 
SDD Subdural Drain 
 
SPD Subperiosteal drain 
 
STEMI ST-segment Elevation Myocardial 
Infarction 
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